ROPIVACAINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ropivacaine Hydrochloride, and when can generic versions of Ropivacaine Hydrochloride launch?
Ropivacaine Hydrochloride is a drug marketed by Amneal, Caplin, Eugia Pharma, Gland Pharma Ltd, Hikma, Hospira, Inforlife, Mylan Labs Ltd, Navinta Llc, Rising, and Somerset Theraps Llc. and is included in thirteen NDAs.
The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ropivacaine Hydrochloride
A generic version of ROPIVACAINE HYDROCHLORIDE was approved as ropivacaine hydrochloride by NAVINTA LLC on July 17th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ROPIVACAINE HYDROCHLORIDE?
- What are the global sales for ROPIVACAINE HYDROCHLORIDE?
- What is Average Wholesale Price for ROPIVACAINE HYDROCHLORIDE?
Summary for ROPIVACAINE HYDROCHLORIDE
![ROPIVACAINE HYDROCHLORIDE drug patent expirations Drug patent expirations by year for ROPIVACAINE HYDROCHLORIDE](/p/graph/s/t/ROPIVACAINE_HYDROCHLORIDE-patent-expirations.png)
Recent Clinical Trials for ROPIVACAINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
McMaster University | Phase 4 |
University of Miami | Phase 4 |
The University of Texas Health Science Center at San Antonio | Phase 2 |
Pharmacology for ROPIVACAINE HYDROCHLORIDE
Drug Class | Amide Local Anesthetic |
Physiological Effect | Local Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for ROPIVACAINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for ROPIVACAINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NAROPIN | Injection | ropivacaine hydrochloride | 2 mg/mL, 200 mL | 020533 | 1 | 2015-09-03 |
NAROPIN | Injection | ropivacaine hydrochloride | 2 mg/mL, 100 mL | 020533 | 1 | 2015-01-30 |
NAROPIN | Injection | ropivacaine hydrochloride | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | 020533 | 1 | 2006-11-13 |
US Patents and Regulatory Information for ROPIVACAINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rising | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 090318-003 | Sep 23, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Mylan Labs Ltd | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 206091-001 | Oct 26, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Somerset Theraps Llc | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 207636-007 | Jun 15, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Somerset Theraps Llc | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 207636-003 | Jun 15, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |